Clinical Assessment

• Diffuse gray-brown to dark brown hyperpigmentation across the malar region, forehead, cheeks, perioral area, and nose
• Small hyperpigmented papules and lichenification (leathery texture)
• Photodistributed pattern (sun-exposed areas predominantly affected)
• Skin phototype IV-V

Detailed Treatment Plan

Step 0 - Critical Foundations (All Conditions)

• Strict photoprotection - daily broad-spectrum SPF ≥30 sunscreen (physical blocker preferred: zinc oxide or titanium dioxide). This is the single most effective intervention. Wear wide-brimmed hats.
• Identify and eliminate triggers - stop any fairness/bleaching creams (especially those containing hydroquinone, mercury, or steroids), oral contraceptives if applicable, and any photosensitizing medications.
• Dermoscopy - distinguishes LPP (blue-gray dots/globules in a follicular pattern) from melasma (pseudonetwork) and ochronosis (curvilinear structures).
• Skin biopsy (punch biopsy) if diagnosis is unclear - this is the gold standard to differentiate LPP (interface dermatitis + dermal melanophages) from ochronosis (banana-shaped ochre deposits in dermis).

Treatment for Lichen Planus Pigmentosus (Most Likely Diagnosis)

First-line

1. Topical Tacrolimus 0.1% ointment (or 0.03% twice daily) - calcineurin inhibitor that suppresses the interface dermatitis driving melanin incontinence. Preferred over steroids for the face. Apply twice daily to affected areas. - Fitzpatrick's Dermatology, p. 1415
2. Topical corticosteroids (mid-potency, e.g., mometasone furoate 0.1% cream) - use with caution on the face; limit to 2-4 weeks to control active inflammation. Avoid long-term use due to risk of atrophy and telangiectasias.
3. Strict sun avoidance - particularly important because the LP actinicus variant (photodistributed LPP) does respond to sun protection, with gradual fading of hyperpigmentation over months. - Andrews' Diseases of the Skin, p. 266

Second-line

1. Low-dose oral isotretinoin (20 mg/day for 6 months) in conjunction with sunscreen - a prospective study showed stabilization and decrease in pigmentation, especially when used early in disease course. - Fitzpatrick's Dermatology, p. 1415
2. Antimalarials (hydroxychloroquine 200-400 mg/day) - used as systemic immunomodulation for refractory LPP.
3. Oral corticosteroids (prednisolone 0.5 mg/kg/day tapered over 4-6 weeks) for rapidly progressive or extensive disease.
4. Topical vitamin A (tretinoin 0.025-0.05%) - helps accelerate fading of postinflammatory pigmentation. Use alternate nights to minimize irritation.

Third-line / Procedural

1. Chemical peels - glycolic acid peels (30-70%) or salicylic acid peels (20-30%) every 4-6 weeks to improve discoloration. - Andrews', p. 266
2. Laser therapy (variable results):
   • Q-switched Nd:YAG laser (1064 nm) - targets dermal melanin
   • Low-fluence Q-switched lasers
   • Non-ablative fractional laser
   • Results are inconsistent; use only after confirming diagnosis, as lasers can worsen LPP if active inflammation is ongoing.

Treatment for Melasma (If Confirmed / Co-existing)

First-line Topicals

Adjunctive Topicals

• L-ascorbic acid (Vitamin C) 10-15% - antioxidant, reduces melanin synthesis
• Kojic acid 1-4% - inhibits tyrosinase
• Tranexamic acid 2-5% topical - reduces melanin production
• Niacinamide 4% - blocks melanosome transfer to keratinocytes

Adjunctive Oral Therapy

• Oral tranexamic acid 250 mg BID for 8-12 weeks - growing evidence base; screen for thromboembolism risk factors before initiating. - Dermatology 2-Volume Set 5e, p. 1345

Procedural (Second/Third-line)

• Chemical peels: glycolic acid (start 30%, increase as tolerated) or salicylic acid (20-30%) every 4-6 weeks
• Non-ablative fractional laser, IPL (intense pulsed light), Low-fluence Q-switched lasers, Picosecond lasers - for refractory cases

Maintenance (Long-term)

• Daily sunscreen + sun protection (ongoing)
• Topical retinoid (tretinoin 0.025%)
• Topical alpha-hydroxy acid (glycolic acid cream)
• Continued use of kojic acid, azelaic acid, or tranexamic acid

Treatment for Exogenous Ochronosis (If Hydroquinone History)

1. Immediately stop all hydroquinone-containing products - this is the most important step. Some spontaneous improvement may occur over months to years after cessation.
2. Q-switched lasers (Q-switched Nd:YAG or ruby) - have shown inconsistent improvement.
3. Intense Pulsed Light (IPL) - some benefit reported.
4. No consistently effective topical therapy exists; hydroquinone and topical corticosteroids are of no benefit and may worsen the condition. - Andrews' Diseases of the Skin, p. 627

Practical Approach for This Patient

1. Take detailed history: duration, use of fairness creams, contraceptives, sun exposure patterns
2. Perform dermoscopy to narrow the differential
3. Start immediately: broad-spectrum SPF 50+ sunscreen twice daily
4. Start topical tacrolimus 0.1% twice daily (for LPP) +/- tretinoin 0.025% at night (for both LPP and melasma)
5. If melasma component: add azelaic acid 15% or Kligman's formula at night
6. Consider punch biopsy if diagnosis remains uncertain after 4-6 weeks of treatment
7. Review at 8-12 weeks - if inadequate response, escalate to oral tranexamic acid or isotretinoin
8. Counsel the patient: pigmentation typically takes 6-12 months to show significant improvement; strict photoprotection is non-negotiable

Revised Assessment: Acne Vulgaris with Severe Post-Acne Sequelae

• Active acne - mild, predominantly comedonal/papular (scattered closed comedones and papules on forehead and temples)
• Severe atrophic acne scarring - mixed pattern of rolling, boxcar, and icepick scars across both cheeks, malar regions, and temples (Grade 4 - scars visible from >50 cm, cannot be flattened by skin stretch)
• Post-inflammatory hyperpigmentation (PIH) - diffuse dark brown/gray-brown discoloration overlying the scarred areas, typical of Fitzpatrick skin type IV-V

Part 1: Treatment of Active Acne

Step-by-Step by Severity

Topical First-line (Start Here)

In darker skin types (this patient's phototype IV-V), adapalene is preferred over tretinoin as it causes less irritation and PIH flare.

Adjunctive Topicals

• Azelaic acid 15-20% - dual benefit: anti-acne AND fades PIH simultaneously. Excellent choice for this patient.
• Niacinamide 4% serum - reduces sebum, decreases PIH, well-tolerated in dark skin
• Salicylic acid 2% wash - comedolytic, reduces follicular plugging

Skincare Advice

• Use a non-comedogenic, gentle cleanser twice daily (no harsh scrubs)
• Non-comedogenic moisturizer - retinoids cause dryness; moisturizing reduces irritation and helps adherence
• Broad-spectrum SPF 30+ sunscreen daily - prevents worsening of PIH from UV exposure (physical blockers: zinc oxide/titanium dioxide preferred - less likely to cause comedones)
• Do NOT pick or squeeze lesions - worsens scarring in already-scarred skin

Systemic Therapy (If Inadequate Topical Response at 8-12 Weeks)

• Doxycycline 100 mg once daily (or 40 mg modified-release) - first-line. Limit to 3-4 months; always combine with topical retinoid + BPO. Never use oral antibiotic as monotherapy.
• Sarecycline - narrow spectrum tetracycline, less resistance risk.
• Avoid minocycline as first-line due to risk of hyperpigmentation (which would worsen this patient's PIH) and autoimmune reactions.

• Combined oral contraceptive pill (OCP with low-androgenic progestin, e.g., norgestimate + ethinyl estradiol) - equivalent to oral antibiotics for inflammatory acne at 6 months. Consider if patient is sexually active and needs contraception.
• Spironolactone 50-100 mg/day - anti-androgen, particularly effective for adult female acne. Monitor potassium.

• Indication here: severe scarring history means even mild active acne warrants consideration. Isotretinoin prevents new scars from forming.
• Dose: 0.5-1 mg/kg/day for a cumulative dose of 120-150 mg/kg
• Mandatory: iPLEDGE pregnancy prevention program (teratogenic), monthly LFTs + lipids
• Achieves long-term remission in ~85% of patients after one course

Part 2: Treatment of Acne Scars (Most Important for This Patient)

PIH (Post-Inflammatory Hyperpigmentation) - Treat First

Atrophic Scar Treatment (By Scar Type)

Rolling Scars (Most Common Here)

• Subcision - needle is passed under the scar to break fibrous tethering bands. Most effective for rolling scars. Can be combined with filler.
• Microneedling (MNRF - Microneedling Radiofrequency) - multiple sessions; stimulates collagen; safe for dark skin, low PIH risk.
• Non-ablative fractional laser (1540 nm or 1550 nm) - multiple sessions (4-6); good for rolling scars; lower risk in dark skin than ablative.

Boxcar Scars

• Non-ablative fractional laser or ablative fractional laser (CO2 or Er:YAG at low fluence) - for shallow to moderate depth.
• Chemical reconstruction of skin scars (CROSS technique) - 65-100% TCA applied focally to the base of each boxcar scar with a toothpick; stimulates fibroplasia.
• Punch excision then closure or grafting for deep boxcar scars.

Icepick Scars

• CROSS technique (focal TCA 65-100%) - treatment of choice for icepick scars; cheapest, most effective.
• Punch excision + suture or punch grafting for isolated deep icepick scars. - Dermatology 2-Volume Set 5e, p. 730

Combined/General Scar Treatments

• Microneedling (dermaroller/dermapen) - 1.5-2.5 mm depth; 4-6 sessions at monthly intervals; stimulates collagen remodeling; safe for skin phototypes IV-VI.
• Platelet-Rich Plasma (PRP) + microneedling - PRP injected into scarred areas augments collagen synthesis.
• CO2 fractional laser resurfacing - most powerful but HIGH risk of PIH/dyspigmentation in dark skin; use only after adequate bleaching pre-treatment + with extreme caution.
• Dermal fillers (poly-L-lactic acid, hyaluronic acid, calcium hydroxylapatite) - temporary volumization of depressed scars. - Dermatology 2-Volume Set 5e, p. 730

Practical Treatment Roadmap for This Patient

Key point: Never treat scars while acne is still active - new inflammation will create new scars and undo procedural work. Stabilize the acne fully first.